| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.45 | 53.21 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 11.82B | 44.08 | 25.05 | 18.49% | 29.63% | 31.37% | 5.36% | 0.09 |
| INBXInhibrx Biosciences, Inc. | 1.07B | 73.28 | 0.63 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.24B | 6.55 | -3.10 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.38B | 7.94 | -3.36 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 987.53M | 10.14 | -5.54 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.07B | 18.72 | -7.20 | 49.59% | -46.83% | -27.21% | 0.18 | |
| TNGXTango Therapeutics, Inc. | 1.41B | 10.44 | -8.77 | 15.17% | -151.15% | -62.81% | 0.18 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 24.65M | 7.66M | 37.04M | 24.86M | 36.53M | 42.07M |
| Revenue Growth % | - | -0.69% | 3.84% | -0.33% | 0.47% | 0.15% |
| Cost of Goods Sold | 32.27M | 1.63M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 1.31% | 0.21% | - | - | - | - |
| Gross Profit | -7.63M | 6.03M | 37.04M | 24.86M | 36.53M | 42.07M |
| Gross Margin % | -0.31% | 0.79% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 1.79% | 5.14% | -0.33% | 0.47% | 0.15% |
| Operating Expenses | 7.54M | 58.23M | 95.23M | 135.93M | 150.7M | 187.66M |
| OpEx % of Revenue | 0.31% | 7.61% | 2.57% | 5.47% | 4.13% | 4.46% |
| Selling, General & Admin | 7.54M | 8.24M | 17.6M | 30.02M | 35.5M | 43.75M |
| SG&A % of Revenue | 0.31% | 1.08% | 0.48% | 1.21% | 0.97% | 1.04% |
| Research & Development | 32.27M | 49.99M | 77.64M | 105.91M | 115.2M | 143.92M |
| R&D % of Revenue | 1.31% | 6.53% | 2.1% | 4.26% | 3.15% | 3.42% |
| Other Operating Expenses | -32.27M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.16M | -52.2M | -58.19M | -111.07M | -114.17M | -145.59M |
| Operating Margin % | -0.62% | -6.82% | -1.57% | -4.47% | -3.13% | -3.46% |
| Operating Income Growth % | - | -2.44% | -0.11% | -0.91% | -0.03% | -0.28% |
| EBITDA | -14.52M | -50.58M | -57.29M | -109.46M | -111.76M | -143.1M |
| EBITDA Margin % | -0.59% | -6.61% | -1.55% | -4.4% | -3.06% | -3.4% |
| EBITDA Growth % | - | -2.48% | -0.13% | -0.91% | -0.02% | -0.28% |
| D&A (Non-Cash Add-back) | 643K | 1.63M | 897K | 1.61M | 2.42M | 2.5M |
| EBIT | -15.16M | -51.97M | -58.19M | -111.07M | -114.17M | -145.59M |
| Net Interest Income | 684K | 108K | 495K | 1.46M | 6.62M | 7.89M |
| Interest Income | 684K | 108K | 495K | 1.46M | 6.62M | 7.89M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.07M | 228K | 247K | 2.95M | 12.56M | 15.5M |
| Pretax Income | -14.1M | -51.97M | -57.94M | -108.12M | -101.61M | -130.09M |
| Pretax Margin % | -0.57% | -6.79% | -1.56% | -4.35% | -2.78% | -3.09% |
| Income Tax | 0 | 0 | 292K | 54K | 134K | 208K |
| Effective Tax Rate % | 1% | 1% | 1.01% | 1% | 1% | 1% |
| Net Income | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M |
| Net Margin % | -0.57% | -6.79% | -1.57% | -4.35% | -2.79% | -3.1% |
| Net Income Growth % | - | -2.69% | -0.12% | -0.86% | 0.06% | -0.28% |
| Net Income (Continuing) | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.57 | -1.62 | -0.94 | -1.23 | -1.08 | -1.19 |
| EPS Growth % | - | -0.03% | 0.42% | -0.31% | 0.12% | -0.1% |
| EPS (Basic) | -1.57 | -1.62 | -0.94 | -1.23 | -1.08 | -1.19 |
| Diluted Shares Outstanding | 8.99M | 31.93M | 62.11M | 87.82M | 94.57M | 109.23M |
| Basic Shares Outstanding | 8.99M | 31.93M | 62.11M | 87.82M | 94.57M | 109.23M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 41.66M | 193.63M | 492.34M | 375.27M | 346.54M | 266.34M |
| Cash & Short-Term Investments | 40.42M | 190.32M | 485.25M | 366.13M | 336.88M | 257.92M |
| Cash Only | 22.89M | 28.38M | 142.75M | 59.97M | 66.39M | 69.53M |
| Short-Term Investments | 17.54M | 161.94M | 342.51M | 306.17M | 270.5M | 188.39M |
| Accounts Receivable | 0 | 2M | 2M | 2M | 0 | 0 |
| Days Sales Outstanding | - | 95.35 | 19.71 | 29.36 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 567K | 7.14M | 9.65M | 8.43M |
| Total Non-Current Assets | 14.11M | 13.62M | 7.82M | 61.2M | 56.03M | 50.15M |
| Property, Plant & Equipment | 11.83M | 11.3M | 6.09M | 57.77M | 53.42M | 47.58M |
| Fixed Asset Turnover | 2.08x | 0.68x | 6.09x | 0.43x | 0.68x | 0.88x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.28M | 2.32M | 1.73M | 3.43M | 2.61M | 2.57M |
| Total Assets | 55.76M | 207.25M | 500.15M | 436.47M | 402.57M | 316.49M |
| Asset Turnover | 0.44x | 0.04x | 0.07x | 0.06x | 0.09x | 0.13x |
| Asset Growth % | - | 2.72% | 1.41% | -0.13% | -0.08% | -0.21% |
| Total Current Liabilities | 25.85M | 40.92M | 40.69M | 55.55M | 45.94M | 38.17M |
| Accounts Payable | 670K | 1.84M | 3.23M | 4.45M | 2.79M | 1.6M |
| Days Payables Outstanding | 7.58 | 413.52 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 19.93M | 793K | 666K | 1.27M | 7.49M | 1.74M |
| Current Ratio | 1.61x | 4.73x | 12.10x | 6.76x | 7.54x | 6.98x |
| Quick Ratio | 1.61x | 4.73x | 12.10x | 6.76x | 7.54x | 6.98x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 22.01M | 127.73M | 114.72M | 131.45M | 103.52M | 78.81M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 7.88M | 6.92M | 0 | 39.36M | 36.84M | 34.04M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14.12M | 5K | 0 | 0 | 0 | 0 |
| Total Liabilities | 47.86M | 168.65M | 155.41M | 186.99M | 149.46M | 116.97M |
| Total Debt | 8.54M | 7.88M | 1.5M | 41.13M | 38.92M | 36.49M |
| Net Debt | -14.35M | -20.5M | -141.24M | -18.84M | -27.46M | -33.04M |
| Debt / Equity | 1.08x | 0.20x | 0.00x | 0.16x | 0.15x | 0.18x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 7.91M | 38.6M | 344.75M | 249.48M | 253.11M | 199.52M |
| Equity Growth % | - | 3.88% | 7.93% | -0.28% | 0.01% | -0.21% |
| Book Value per Share | 0.88 | 1.21 | 5.55 | 2.84 | 2.68 | 1.83 |
| Total Shareholders' Equity | 7.91M | 38.6M | 344.75M | 249.48M | 253.11M | 199.52M |
| Common Stock | 13K | 40K | 88K | 88K | 102K | 108K |
| Retained Earnings | -51.13M | -103.1M | -161.34M | -269.51M | -371.26M | -501.56M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 10K | 17K | -765K | -3.71M | 186K | 336K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -24.8M | 70.07M | -59.53M | -109.08M | -117.98M | -131.5M |
| Operating CF Margin % | -1.01% | 9.15% | -1.61% | -4.39% | -3.23% | -3.13% |
| Operating CF Growth % | - | 3.83% | -1.85% | -0.83% | -0.08% | -0.11% |
| Net Income | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M |
| Depreciation & Amortization | 643K | 718K | 897K | 1.61M | 2.42M | 2.5M |
| Stock-Based Compensation | 1.69M | 1.76M | 7.83M | 14.23M | 19.08M | 28.9M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -14.74M | 890K | 1.32M | 1.75M | 234K | -849K |
| Working Capital Changes | 1.7M | 118.67M | -11.35M | -18.49M | -37.97M | -31.75M |
| Change in Receivables | 0 | -2M | 0 | 0 | 2M | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 1.17M | 1.23M | 1.1M | -1.71M | -1.18M |
| Cash from Investing | 848K | -145.47M | -183.43M | 26.4M | 41.43M | 86.13M |
| Capital Expenditures | -1.82M | -1.11M | -1.84M | -7.69M | -1.53M | -754K |
| CapEx % of Revenue | 0.07% | 0.14% | 0.05% | 0.31% | 0.04% | 0.02% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 2.67M | -40K | 0 | 0 | 0 | 0 |
| Cash from Financing | 11M | 80.88M | 357.32M | 1.61M | 82.41M | 47.66M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 11M | 40K | -14.78M | 1.61M | 2.39M | 5.94M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -26.62M | 68.97M | -61.36M | -116.77M | -119.51M | -132.25M |
| FCF Margin % | -1.08% | 9.01% | -1.66% | -4.7% | -3.27% | -3.14% |
| FCF Growth % | - | 3.59% | -1.89% | -0.9% | -0.02% | -0.11% |
| FCF per Share | -2.96 | 2.16 | -0.99 | -1.33 | -1.26 | -1.21 |
| FCF Conversion (FCF/Net Income) | 1.76x | -1.35x | 1.02x | 1.01x | 1.16x | 1.01x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -178.3% | -223.51% | -30.38% | -36.41% | -40.49% | -57.58% |
| Return on Invested Capital (ROIC) | - | -671.64% | -39.39% | -38.38% | -37.53% | -55.69% |
| Gross Margin | -30.93% | 78.77% | 100% | 100% | 100% | 100% |
| Net Margin | -57.18% | -678.84% | -157.21% | -435.14% | -278.54% | -309.73% |
| Debt / Equity | 1.08x | 0.20x | 0.00x | 0.16x | 0.15x | 0.18x |
| FCF Conversion | 1.76x | -1.35x | 1.02x | 1.01x | 1.16x | 1.01x |
| Revenue Growth | - | -68.94% | 383.83% | -32.89% | 46.93% | 15.17% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Collaboration Revenue | 26.04M | 24.86M | 31.53M | 29.97M |
| Collaboration Revenue Growth | - | -4.54% | 26.82% | -4.94% |
| License Revenue | 11M | - | 5M | 12.1M |
| License Revenue Growth | - | - | - | 142.00% |
Tango Therapeutics, Inc. (TNGX) reported $66.5M in revenue for fiscal year 2024. This represents a 170% increase from $24.6M in 2019.
Tango Therapeutics, Inc. (TNGX) grew revenue by 15.2% over the past year. This is strong growth.
Tango Therapeutics, Inc. (TNGX) reported a net loss of $100.5M for fiscal year 2024.
Tango Therapeutics, Inc. (TNGX) has a return on equity (ROE) of -57.6%. Negative ROE indicates the company is unprofitable.
Tango Therapeutics, Inc. (TNGX) had negative free cash flow of $146.8M in fiscal year 2024, likely due to heavy capital investments.